Eduardo Anitua1,2, Francisco Muruzabal1, María de la Fuente1, Jesús Merayo3, Juan Durán4,5, Gorka Orive1,2. 1. a Department of R&D , Biotechnology Institute (BTI) , Vitoria , Spain. 2. b Department of R&D , Fundación Eduardo Anitua , Vitoria , Spain. 3. c Fundación de Investigación Oftalmológica , Instituto Oftalmológico Fernández-Vega , Oviedo , Spain. 4. d Department of R&D , Instituto Clínico-Quirúrgico de Oftalmología , Bilbao , Spain. 5. e Department of Ophthalmology, School of Medicine and Dentistry, BioCruces Health Research Institute , University of the Basque Country , Leioa , Spain.
Abstract
PURPOSE: The purpose of this work is to describe and review the technology of plasma rich in growth factors (PRGF), a novel blood derivative product, in the treatment of ocular surface disorders. METHODS: To demonstrate the importance of this technology in the treatment of ocular pathologies, a thorough review of the preclinical and clinical literature results obtained following use of the different therapeutic formulations of PRGF was carried out. A literature search for applications of PGRF plasma in the ophthalmology field was carried out using the PubMed database. RESULTS: PRGF involves the use of patient's own biologically active proteins, growth factors, and biomaterial scaffolds for therapeutic purposes. This procedural technology is gaining interest in regenerative medicine due to its potential to stimulate and accelerate the tissue healing processes. The versatility and biocompatibility of this technology opens the door to a personalized medicine on ocular tissue regeneration. This review discusses the state of the art of the new treatments and technologies developed to promote ocular surface tissue regeneration. The standardized protocol that has been developed to source eye drops from PRGF technology is also described. The preclinical research, together with the most relevant clinical applications are summarized and discussed. CONCLUSIONS: The preliminary results suggest that the use of PRGF to enhance ocular tissue regeneration is safe and efficient.
PURPOSE: The purpose of this work is to describe and review the technology of plasma rich in growth factors (PRGF), a novel blood derivative product, in the treatment of ocular surface disorders. METHODS: To demonstrate the importance of this technology in the treatment of ocular pathologies, a thorough review of the preclinical and clinical literature results obtained following use of the different therapeutic formulations of PRGF was carried out. A literature search for applications of PGRF plasma in the ophthalmology field was carried out using the PubMed database. RESULTS: PRGF involves the use of patient's own biologically active proteins, growth factors, and biomaterial scaffolds for therapeutic purposes. This procedural technology is gaining interest in regenerative medicine due to its potential to stimulate and accelerate the tissue healing processes. The versatility and biocompatibility of this technology opens the door to a personalized medicine on ocular tissue regeneration. This review discusses the state of the art of the new treatments and technologies developed to promote ocular surface tissue regeneration. The standardized protocol that has been developed to source eye drops from PRGF technology is also described. The preclinical research, together with the most relevant clinical applications are summarized and discussed. CONCLUSIONS: The preliminary results suggest that the use of PRGF to enhance ocular tissue regeneration is safe and efficient.
Authors: Ronald Mauricio Sanchez-Avila; Jesus Merayo-Lloves; Ana Cristina Riestra; Luis Fernandez-Vega Cueto; Eduardo Anitua; Leire Begoña; Francisco Muruzabal; Gorka Orive Journal: Int Ophthalmol Date: 2017-06-15 Impact factor: 2.031
Authors: Alfonso L Sabater; Hazem M Mousa; Xavier Quinones; Felipe Valenzuela; Ronald Mauricio Sanchez Avila; Gorka Orive; Eduardo Anitua; Jesús Merayo; Victor L Perez Journal: Int Ophthalmol Date: 2021-03-21 Impact factor: 2.031
Authors: Ronald M Sánchez-Ávila; Edmar Uribe-Badillo; Carlos Fernández-Vega González; Francisco Muruzabal; Borja de la Sen-Corcuera; Begoña Baamonde; Luis M Quirós; Eduardo Anitua; Jesús Merayo-Lloves Journal: Vision (Basel) Date: 2021-07-02
Authors: James L Liu; Kevin Y Chu; Andrew T Gabrielson; Run Wang; Landon Trost; Gregory Broderick; Kelvin Davies; Gerald Brock; John Mulhall; Ranjith Ramasamy; Trinity J Bivalacqua Journal: Sex Med Date: 2021-05-14 Impact factor: 2.491
Authors: Ronald M Sanchez-Avila; Jesús Merayo-Lloves; Ana C Riestra; Silvia Berisa; Carlos Lisa; José Alfonso Sánchez; Francisco Muruzabal; Gorka Orive; Eduardo Anitua Journal: Medicine (Baltimore) Date: 2018-04 Impact factor: 1.889
Authors: Eduardo Anitua; María de la Fuente; Francisco Muruzabal; Ronald Mauricio Sánchez-Ávila; Jesús Merayo-Lloves; Mikel Azkargorta; Felix Elortza; Gorka Orive Journal: PLoS One Date: 2018-10-12 Impact factor: 3.240
Authors: Borja de la Sen-Corcuera; Jesús Montero-Iruzubieta; Ronald M Sánchez-Ávila; Gorka Orive; Eduardo Anitua; Manuel Caro-Magdaleno; Jesús Merayo-Lloves Journal: Clin Ophthalmol Date: 2020-06-17
Authors: Ronald M Sánchez-Avila; Jesus Merayo-Lloves; Maria Laura Fernández; Luis Alberto Rodríguez-Gutiérrez; Pedro Pablo Rodríguez-Calvo; Andres Fernández-Vega Cueto; Francisco Muruzabal; Gorka Orive; Eduardo Anitua Journal: Int Med Case Rep J Date: 2018-05-01
Authors: Eduardo Anitua; María de la Fuente; Ignacio Alcalde; Cristina Sanchez; Jesús Merayo-Lloves; Francisco Muruzabal Journal: Transl Vis Sci Technol Date: 2020-06-25 Impact factor: 3.283
Authors: Ronald M Sánchez-Ávila; Álvaro Fernández-Vega González; Álvaro Fernández-Vega Sanz; Jesús Merayo-Lloves Journal: Int Med Case Rep J Date: 2019-07-12